Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P220020/S005

Lava Liquid Embolic System (Lava LES) and Lava Mixing Kit

Sirtex Medical, Inc. · Decision date Sep 3, 2025

FDA DECISIONP220020/S005

What did the FDA approve?

FDA records P220020/S005 as a supplement to PMA P220020, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Sep 3, 2025.

FDA approval order statement

Approval for a contract manufacturing site located in Wilmington, Massachusetts and to change the legal manufacturer address
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Cardiovascular
Decision date
Sep 3, 2025
FDA change category
Location Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P220020/S005
Regulatory pathway
PMA supplement
Product code
QVG
Decision code
APPR
Decision date
Sep 3, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Embolization Agent, Vascular.

Product code
QVG
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P220020/S005 received

    Application receipt date recorded by FDA.

  2. P220020/S007 · Related supplement

    Lava Liquid Embolic System (Lava LES) and Lava Mixing Kit

  3. P220020/S005 · FDA decision

    Normal 180 Day Track No User Fee

  4. P220020/S008 · Related supplement

    Lava Liquid Embolic System (Lava LES)

Timeline entries are records held by MedtechLedger for P220020. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P220020

Product / regulatory recordCompanyPathwayDecision dateSource
Sirtex Medical, Inc.PMA supplementAug 5, 2025FDA
Sirtex Medical, Inc.PMA supplementJul 9, 2026FDA

Explore the linked device profile

Other records with product code QVG

Product / regulatory recordCompanyPathwayDecision dateSource
Instylla, Inc.PMA supplementOct 23, 2026FDA
Instylla, Inc.PMA supplementOct 23, 2026FDA
Instylla, Inc.PMA supplementOct 21, 2026FDA
Instylla, Inc.PMA supplementSep 3, 2026FDA
Instylla, Inc.PMA supplementApr 2, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Sirtex Medical, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
300 Unicorn Park Dr., 2nd Floor ,, Woburn, MA, 01801

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records